Adalimumab
1
Reactions 1477, p5 - 9 Nov 2013 ★ Adalimumab Halo naevi (first report) and deterioration of vitiligo: 2 case reports One man developed new-onset halo naevi and another man developed a deterioration of his existing vitiligo during treatment with SC adalimumab 40mg every alternate week for long-standing ankylosing spondylitis. A 30-year-old man, with no personal or family history of halo naevi, began receiving adalimumab and, within 6 months, he presented with more than 10 halo naevi on his limbs and trunk. Several junctional naevi were surrounded by a peripheral ring of depigmentation. There were no dysplastic features. He continued receiving adalimumab and had no further progression of his skin condition. A 57-year-old man, who had a history of stable vitiligo with a single depigmented macule on his foot (unchanged for 20 years), began receiving adalimumab. Within 3 months, he developed rapid deterioration of his vitiligo and presented with a symmetrical distribution of numerous well-demarcated depigmented macules on his hands, face and axillae. Initial topical treatment with clobetasol and tacrolimus was unsuccessful and adalimumab was then withdrawn. Partial repigmentation was subsequently observed with continued topical treatment. Author comment: "Our cases represent the fifth case of vitiligo and the second case of halo naevi attributable to anti- TNF therapies". Maruthappu T, et al. Deterioration of vitiligo and new onset of halo naevi observed in two patients receiving adalimumab. Dermatologic Therapy 26: 370-372, No. 4, Aug 2013. Available from: URL: http://dx.doi.org/10.1111/dth/.12002 - United Kingdom 803095277 » Editorial comment: A search of AdisBase, Medline and Embase did not reveal any previous case reports of halo naevus associated with adalimumab. The WHO ADR database contained 70 reports of melanocytic naevus associated with adalimumab. 1 Reactions 9 Nov 2013 No. 1477 0114-9954/13/1477-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Transcript of Adalimumab
Reactions 1477, p5 - 9 Nov 2013
★Adalimumab
Halo naevi (first report) and deterioration of vitiligo:2 case reports
One man developed new-onset halo naevi and another mandeveloped a deterioration of his existing vitiligo duringtreatment with SC adalimumab 40mg every alternate week forlong-standing ankylosing spondylitis.
A 30-year-old man, with no personal or family history ofhalo naevi, began receiving adalimumab and, within 6 months,he presented with more than 10 halo naevi on his limbs andtrunk. Several junctional naevi were surrounded by aperipheral ring of depigmentation. There were no dysplasticfeatures. He continued receiving adalimumab and had nofurther progression of his skin condition.
A 57-year-old man, who had a history of stable vitiligo with asingle depigmented macule on his foot (unchanged for20 years), began receiving adalimumab. Within 3 months, hedeveloped rapid deterioration of his vitiligo and presented witha symmetrical distribution of numerous well-demarcateddepigmented macules on his hands, face and axillae. Initialtopical treatment with clobetasol and tacrolimus wasunsuccessful and adalimumab was then withdrawn. Partialrepigmentation was subsequently observed with continuedtopical treatment.
Author comment: "Our cases represent the fifth case ofvitiligo and the second case of halo naevi attributable to anti-TNF therapies".Maruthappu T, et al. Deterioration of vitiligo and new onset of halo naevi observedin two patients receiving adalimumab. Dermatologic Therapy 26: 370-372, No. 4,Aug 2013. Available from: URL: http://dx.doi.org/10.1111/dth/.12002 - UnitedKingdom 803095277
» Editorial comment: A search of AdisBase, Medline andEmbase did not reveal any previous case reports of halo naevusassociated with adalimumab. The WHO ADR databasecontained 70 reports of melanocytic naevus associated withadalimumab.
1
Reactions 9 Nov 2013 No. 14770114-9954/13/1477-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
